I usually do a post-Logi write-up with my top 5 takeaways. Not this time.
This year, one takeaway hit harder than all the others combined.
We sat down with the full team from a large Pharma prospect, and one of the first things they said was:
“Guys, we’re confused. Everybody out there is saying they can do the same thing. AI, agents, prediction, workflows, automation. I don’t know what to believe.”
That, right there, was my biggest takeaway from LogiPharma.
Because yes, the industry has caught up to the message PAXAFE started pushing 6+ years ago.
AI in logistics.
Decision support via elimination of silos.
Prediction.
Workflow automation.
Data-agnostic control towers.
Reducing alert noise.
Connecting planning, logistics and quality.
None of that sounds fringe anymore. Good.
It means the market has matured. But it also means something else:
The gap between who can say the words and who can actually deliver the outcome is now massive.
And that is where extra up-front discipline & diligence is required.
Because the next few years are going to be filled with demos, decks, and buzzwords that sound eerily similar.
So if you’re trying to separate what’s real from what’s theater, here are 4 questions worth asking.
This one is simple. If a provider is selling you “automation,” “agents,” and “workflow intelligence”, but the services bill is enormous, something probably doesn’t add up.
Why?
Because truly automated workflows should reduce manual support.
Agents that actually take first-priority action should reduce noise & unlock managing by exception.
A robust ingestion layer should make integrations cheap & seamless.
An end-to-end product should eliminate silos & friction, not demand more people to work around silos & friction.
So if your services bill looks like a second mortgage, there are usually only a few explanations:
The tech is weak and needs to be propped up by people.
The workflows are not actually automated.
The implementation model is too brittle.
Or the product is simply not built out enough yet.
At the end of the day, the truth usually shows up in the bottom line.
If you’re being sold “agentic this” and “automated that,” yet half of the value is still coming from armies of people behind the curtain (whilst you are moving towards a digitally-native model), then more pointed questions are necessary.
This is where the conversation gets much more serious.
Being able to integrate with another provider is not the same thing as owning the data pipe.
It is not enough to say, “yes, we can ingest the data.”
Great.
Now what?
Can you normalize all of the different data schemas & data formats?
Can you contextualize conflicting data sources into proper root cause & action?
Can you make it usable across planning, logistics, and quality?
Can you turn fragmented operational data into a coherent system that supports decisions in real time?
That is a very different problem.
Real data harmonization is not just:
N vendors × M formats × K configurations.
It is semantic complexity:
How a shipment gets created.
How a device gets closed out.
What constitutes a complete shipment record.
Whether the source of truth comes from a milestone, a geofence, a light sensor, a button press, a timeout, a proof of delivery document, or some ugly combination of the above.
And here’s the hard part:
Much of that logic is not documented cleanly anywhere.
It lives in tribal knowledge. It varies by region, by product, by lane:
In buried SOPs.
In exception handling habits.
In quality teams.
In operations teams.
In planning teams.
In local workflows that were never designed for machine reasoning.
An LLM does not magically infer all of that from raw data.
It requires production exposure, context. structured logic, validation and the ability to deal with edge cases.
Although in Pharma, “edge case” is usually just another word for “the case that matters most.”
This is also why the biggest barrier to AI-driven automation in pharma logistics is often not the AI itself.
It is the way operational knowledge is structured, or more accurately, not structured.
And once you understand that, you understand why owning the full pipe matters.
Because real decision intelligence in cold chain is closed-loop by nature.
Take something like stability budget.
That calculation depends on:
And can be enhanced by:
Packaging properties.
Excursion behavior.
And quality context across prior shipment legs.
Remove one of those inputs and the calculation starts to break.
And that derivative data point then becomes an input into other data or process streams, models or logic, like live shipment risk, intervention prioritization, or release workflows.
This is the difference between building an isolated alerting tool and building an actual operating system for decisions.
You can absolutely build a temp alert module or risk score in isolation, but the utility of both starts to collapse when they’re disconnected from the broader context needed to make the next decision.
The market has clearly moved. We saw this years ago.
Pharma was always going to demand more agnostic solutions.
It was inevitable.
One platform.
One series of trainings.
Apples-to-apples data.
True. Interoperability.
A system that is continuously improving and self-optimizing.
The ability to work across multiple devices, packagers, carriers, and logistics partners without being trapped inside one commercial relationship.
That is the direction of travel. And to be fair, over the last 12 months, more providers from adjacent parts of the ecosystem have started using the word “agnostic.”
Again, good.
But Pharma should ask the obvious follow-up question:
How agnostic can a provider really be when they still have a horse in the race?
Because the commercial reality is straightforward.
If you sell your own hardware, packaging, or logistics services, your competitors may not be especially eager to pipe their raw operational data directly into your system.
And honestly, that hesitation is rational.
There is competitive intelligence embedded in that data.
Performance fingerprints.
Operational signals.
Behavioral patterns.
Exposure points for competitors to exploit.
For more established providers especially, handing over raw, unrefined data to a competitor is a difficult pill to swallow.
Which is why the cleanest long-term answer is often a neutral third party.
A provider with no hardware to push.
No packaging agenda.
No freight forwarding agenda.
No conflict around the raw signal.
That creates something Pharma increasingly wants:
A real separation of powers.
A system of record that neither side can manipulate for its own commercial interest.
A trust layer.
And in a world where more cold chain decisions are being automated, recommended, or escalated by software, that trust layer matters a lot.
Every pharma company is at a slightly different maturity and adoption curve when it comes to their tech stack pertaining to Lane Qualification, Visibility, QA Product Release and Insights & Analytics.
They may be using provider X for qualification, providers Y and Z for visibility, internal teams for product QA, and projects & consultants for insights.
PAXAFE’s argument from day one is that why in the world would you want to piece meal this to begin with? Our foundational hypothesis from day 1 is that Pharma will not get to 100% OTIF so long as these technologies, datasets and decisions happen in different platforms, with data that does not semantically speak each others’ language.
That said, the most important part of the equation here is not the application!!
It is the underlying data infrastructure that ties all of this data together, and gives it context and meaning.
At PAXAFE, our raw data ingestion layer acts as the FOUNDRY.
And our intelligence layer acts as the REASONING ONTOLOGY.
Some use these layers to feed into their own applications. Or their desired applications of choice that they are already working with.
At the end of the day, the hardest and most important piece to solve for: garbage in, garbage out.
I welcome the fact that the market has caught up. A rising tide lifts all boats.
We’ve spent years arguing that cold chain would move beyond dots on a map, passive dashboards. disconnected data and visibility theater. (see image above from LogiPharma in 2021)
That day is here. But vocabulary parity is not capability parity.
Anyone can say AI.
Anyone can say agents.
Anyone can say workflow.
Anyone can say agnostic.
The harder question is whether the architecture underneath those words can actually support the outcome being promised.
And the architecture for shipping retail goods is one thing.
But the architecture for Life Sciences shipping the world's most important & sensitive products in the world? That requires a different level of architecture.
Can it reduce services dependence?
Can it ingest and harmonize data at scale?
Can it preserve context across planning, logistics, and quality?
Can it act as a neutral source of truth?
Is GxP baked into the SDLC, and can the solution truly withstand a GxP audit?
Can it generate decisions that are not only intelligent, but auditable and operationally usable?
That is where separation takes place.
The next era of Pharma logistics will not be won by whoever shouts “AI” the loudest. It will be won by whoever built the trust layer underneath it.
And if you’re in Pharma trying to separate signal from noise, that’s where I’d start.